Share capital (Details) SFr / shares in Units, $ / shares in Units, $ in Millions |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 13, 2023
CHF (SFr)
SFr / shares
shares
|
Nov. 27, 2023
SFr / shares
shares
|
Jun. 14, 2023
CHF (SFr)
SFr / shares
shares
|
Apr. 03, 2023
CHF (SFr)
SFr / shares
shares
|
Apr. 03, 2023
USD ($)
$ / shares
shares
|
Dec. 15, 2022
CHF (SFr)
SFr / shares
shares
|
Oct. 31, 2022
CHF (SFr)
SFr / shares
shares
|
Oct. 26, 2022
EquityInstruments
SFr / shares
shares
|
Jul. 22, 2022
CHF (SFr)
SFr / shares
shares
|
Jul. 22, 2022
USD ($)
$ / shares
shares
|
Feb. 02, 2022
CHF (SFr)
SFr / shares
shares
|
Dec. 31, 2023
CHF (SFr)
SFr / shares
shares
|
Sep. 30, 2022
EquityInstruments
|
Dec. 31, 2022
CHF (SFr)
EquityInstruments
SFr / shares
shares
|
Sep. 30, 2022
EquityInstruments
|
Dec. 31, 2023
CHF (SFr)
SFr / shares
shares
|
Dec. 31, 2022
CHF (SFr)
SFr / shares
shares
|
Dec. 31, 2021
CHF (SFr)
shares
|
Dec. 12, 2023
CHF (SFr)
|
Oct. 23, 2023 |
Oct. 22, 2023 |
Jun. 13, 2023
CHF (SFr)
|
Dec. 14, 2022
CHF (SFr)
|
Oct. 30, 2022
CHF (SFr)
|
Jul. 19, 2022
CHF (SFr)
SFr / shares
|
Jul. 18, 2022
SFr / shares
|
|
Share capital | ||||||||||||||||||||||||||
Number of shares at beginning of period | (38,214,291) | |||||||||||||||||||||||||
Number of shares at beginning of period | 77,134,020 | 37,898,149 | ||||||||||||||||||||||||
Issue of shares-exercise ESOP & ESC | 12,527,235 | 17,438,883 | 12,527,235 | 17,438,883 | ||||||||||||||||||||||
Sale of shares under shelf registration | 7,999,998 | 4,500,000 | ||||||||||||||||||||||||
Exercise of pre-funded warrants | 17,458,950 | 6,120,000 | 23,578,950 | 15,978,570 | ||||||||||||||||||||||
Sale of shares under sale agency agreement | 4,006,373 | 1,355,248 | ||||||||||||||||||||||||
Net purchase of shares under liquidity agreement | (43,872) | (36,830) | ||||||||||||||||||||||||
Acquisition of shares forfeited from DSPPP | (7,311) | |||||||||||||||||||||||||
Number of shares at end of period | (59,159,103) | (38,214,291) | (59,159,103) | (38,214,291) | ||||||||||||||||||||||
Number of shares at end of period | 125,195,393 | 77,134,020 | 125,195,393 | 77,134,020 | 37,898,149 | |||||||||||||||||||||
Number of shares reclassed as treasury shares under IFRS 2 | (12,527,235) | (17,438,883) | ||||||||||||||||||||||||
Number of shares reclassed as treasury shares under IFRS 2 | (29,958,807) | (17,438,883) | (29,958,807) | (17,438,883) | ||||||||||||||||||||||
Number of shares including IFRS 2 shares | 95,236,586 | 59,695,137 | 95,236,586 | 59,695,137 | ||||||||||||||||||||||
Share capital as registered in commercial register | SFr | SFr 1,782,344.96 | SFr 1,782,344.96 | ||||||||||||||||||||||||
Number of shares registered in commercial register | 178,234,496 | 178,234,496 | ||||||||||||||||||||||||
Number of shares represented by one depositary receipt | 120 | 6 | ||||||||||||||||||||||||
ADS reverse split ratio | 0.05 | |||||||||||||||||||||||||
Par value per share | SFr / shares | SFr 0.01 | SFr 0.01 | SFr 0.01 | SFr 0.01 | SFr 0.01 | SFr 0.01 | SFr 0.01 | SFr 1.00 | ||||||||||||||||||
Treasury shares | SFr | SFr 909,566 | SFr 6,278,763 | SFr 909,566 | SFr 6,278,763 | ||||||||||||||||||||||
Gross amount of treasury shares sold | SFr | 1,193,074 | 464,954 | ||||||||||||||||||||||||
Share capital | SFr | SFr 1,782,345 | SFr 1,329,483 | SFr 1,153,483 | SFr 979,094 | 1,843,545 | 1,153,483 | 1,843,545 | 1,153,483 | SFr 1,329,483 | SFr 1,153,483 | SFr 979,094 | SFr 652,730 | SFr 652,730 | |||||||||||||
Number of new shares issued | 45,286,185 | |||||||||||||||||||||||||
Number of shares issued from conditional capital | 29,986,185 | |||||||||||||||||||||||||
Strike price of equity incentive units | SFr / shares | SFr 0.043 | SFr 0.13 | ||||||||||||||||||||||||
Number of equity incentive units exercised | EquityInstruments | 17,438,883 | |||||||||||||||||||||||||
Other equity interest | SFr | 64,620,223 | 64,620,223 | 64,620,223 | 64,620,223 | SFr 64,600,000 | |||||||||||||||||||||
Share issuance cost | SFr | SFr 30,804 | SFr 288,131 | SFr 1,865,475 | |||||||||||||||||||||||
Addex Pharma SA | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Issue of shares-treasury shares | 15,300,000 | 17,600,000 | 32,636,476 | 16,000,000 | ||||||||||||||||||||||
Issue price | SFr / shares | SFr 0.01 | SFr 0.01 | SFr 0.01 | SFr 1.00 | ||||||||||||||||||||||
Proportion of ownership interest in subsidiary | 100.00% | 100.00% | 100.00% | |||||||||||||||||||||||
Share issuance cost | SFr | SFr 200,000 | |||||||||||||||||||||||||
Kepler | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Sale of shares under sale agency agreement | 4,006,373 | 1,355,248 | ||||||||||||||||||||||||
Issue price | SFr / shares | SFr 0.30 | SFr 0.34 | ||||||||||||||||||||||||
Gross amount of treasury shares sold | SFr | SFr 1,193,074 | SFr 464,954 | ||||||||||||||||||||||||
Kepler | Treasury Shares Reserve | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Treasury shares | SFr | 172,072 | 128,200 | 172,072 | 128,200 | ||||||||||||||||||||||
Kepler | Other financial assets | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Treasury shares | SFr | SFr 848 | SFr 3,165 | SFr 848 | SFr 3,165 | ||||||||||||||||||||||
One institutional investor | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Sale of shares under shelf registration | 7,999,998 | 7,999,998 | 4,500,000 | 4,500,000 | ||||||||||||||||||||||
Exercise of pre-funded warrants | 6,120,000 | 23,578,950 | ||||||||||||||||||||||||
Share sale price | (per share) | SFr 0.14 | $ 0.16 | SFr 0.27 | $ 0.28 | ||||||||||||||||||||||
Number of pre-funded warrants sold | 23,578,950 | 23,578,950 | 10,500,000 | 10,500,000 | ||||||||||||||||||||||
Warrants sale price | (per share) | SFr 0.14 | $ 0.16 | SFr 0.27 | $ 0.28 | ||||||||||||||||||||||
Gross proceeds | SFr 4,500,000 | $ 5.0 | SFr 4,100,000 | $ 4.2 | ||||||||||||||||||||||
Share issuance cost | SFr | SFr 200,000 | |||||||||||||||||||||||||
Number of warrants issued | 31,578,948 | 31,578,948 | 15,000,000 | 15,000,000 | ||||||||||||||||||||||
Strike price of issued warrants | (per share) | SFr 0.15 | $ 0.17 | SFr 0.30 | $ 0.32 | ||||||||||||||||||||||
Value of issued warrants | SFr | SFr 1,780,000 | SFr 1,000,000.0 | ||||||||||||||||||||||||
Reduction in strike price of issued warrants | (per share) | SFr 0.15 | $ 0.17 | ||||||||||||||||||||||||
Number of warrants issued in 2021 with reduced strike price | 9,230,772 | 9,230,772 | ||||||||||||||||||||||||
Number of warrants issued in 2022 with reduced strike price | 15,000,000 | 15,000,000 | ||||||||||||||||||||||||
Number of warrants held by the investor | 55,809,720 | 55,809,720 | ||||||||||||||||||||||||
Increase (decrease) in fair value of warrants due to amendment in exercise conditions | SFr | SFr 960,000 | |||||||||||||||||||||||||
Number of pre-funded warrants exercised | EquityInstruments | 3,960,000 | 6,540,000 | 5,478,570 | |||||||||||||||||||||||
Exercise period of issued warrants | 5 years | 5 years | ||||||||||||||||||||||||
Common shares | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Number of shares at beginning of period | 115,348,311 | 49,272,952 | ||||||||||||||||||||||||
Issue of shares-treasury shares | 32,900,000 | 48,636,476 | ||||||||||||||||||||||||
Issue of shares-exercise ESOP & ESC | 12,527,235 | 17,438,883 | ||||||||||||||||||||||||
Exercise of pre-funded warrants | 23,578,950 | |||||||||||||||||||||||||
Number of shares at end of period | 184,354,496 | 115,348,311 | 184,354,496 | 115,348,311 | 49,272,952 | |||||||||||||||||||||
Number of common shares including IFRS 2 shares | 184,354,496 | 115,348,311 | 184,354,496 | 115,348,311 | ||||||||||||||||||||||
Treasury shares | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Number of shares at beginning of period | (38,214,291) | (11,374,803) | ||||||||||||||||||||||||
Issue of shares-treasury shares | (32,900,000) | (48,636,476) | ||||||||||||||||||||||||
Sale of shares under shelf registration | 7,999,998 | 4,500,000 | ||||||||||||||||||||||||
Exercise of pre-funded warrants | 15,978,570 | |||||||||||||||||||||||||
Sale of shares under sale agency agreement | 4,006,373 | 1,355,248 | ||||||||||||||||||||||||
Net purchase of shares under liquidity agreement | (43,872) | (36,830) | ||||||||||||||||||||||||
Acquisition of shares forfeited from DSPPP | (7,311) | |||||||||||||||||||||||||
Number of shares at end of period | (59,159,103) | (38,214,291) | (59,159,103) | (38,214,291) | (11,374,803) | |||||||||||||||||||||
Number of shares reclassed as treasury shares under IFRS 2 | (29,958,807) | (17,438,833) | (29,958,807) | (17,438,833) | ||||||||||||||||||||||
Number of shares including IFRS 2 shares | (89,117,910) | (55,653,174) | (89,117,910) | (55,653,174) | ||||||||||||||||||||||
American Depositary Shares | One institutional investor | ||||||||||||||||||||||||||
Share capital | ||||||||||||||||||||||||||
Share sale price | (per share) | SFr 17.20 | $ 19.00 | SFr 32.69 | $ 34.00 | ||||||||||||||||||||||
Warrants sale price | (per share) | 17.02 | 18.80 | 32.50 | 33.80 | ||||||||||||||||||||||
Strike price of issued warrants | (per share) | 18.11 | 20.00 | SFr 36.54 | $ 38.00 | ||||||||||||||||||||||
Reduction in strike price of issued warrants | (per share) | SFr 18.11 | $ 20.00 | ||||||||||||||||||||||||
Number of warrants held by the investor | 465,081 | 465,081 |